Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.00−0.06 (-1.48%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies operating margin
Operating margin is operating income as a percentage of revenue.
Taysha Gene Therapies's operating margin for the twelve months ending Jun 30, 2026 was -2792.3%. For fiscal 2025 it was -1130.6%, against -1097.6% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1130.6% | −33.1 |
| FY2024 | Dec 31, 2024 | -1097.6% | −628.7 |
| FY2023 | Dec 31, 2023 | -468.8% | +6023.9 |
| FY2022 | Dec 31, 2022 | -6492.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -516.0% | +932.5 |
| Q2 FY2025 | Jun 30, 2025 | -1347.1% | +568.3 |
| Q1 FY2025 | Mar 31, 2025 | -930.5% | −217.3 |
| Q4 FY2024 | Dec 31, 2024 | -985.8% | −535.0 |
| Q3 FY2024 | Sep 30, 2024 | -1448.4% | −1106.0 |
| Q2 FY2024 | Jun 30, 2024 | -1915.4% | −939.0 |
| Q1 FY2024 | Mar 31, 2024 | -713.3% | −361.4 |
| Q4 FY2023 | Dec 31, 2023 | -450.8% | – |
| Q3 FY2023 | Sep 30, 2023 | -342.4% | – |
| Q2 FY2023 | Jun 30, 2023 | -976.4% | – |
| Q1 FY2023 | Mar 31, 2023 | -351.9% | – |
See a number that looks wrong?